{"name":"Enterprise Therapeutics Ltd","slug":"enterprise-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ETD001 single dose","genericName":"ETD001 single dose","slug":"etd001-single-dose","indication":"Other","status":"phase_1"},{"name":"ETD001 multiple twice daily doses","genericName":"ETD001 multiple twice daily doses","slug":"etd001-multiple-twice-daily-doses","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ETD001 single dose","genericName":"ETD001 single dose","slug":"etd001-single-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ETD001 multiple twice daily doses","genericName":"ETD001 multiple twice daily doses","slug":"etd001-multiple-twice-daily-doses","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPRmtYZ3FyQmJ6WGplejNCTUJ2Q1ktcnc4Sk1TRk5WWGp0STBxUDY0ZFIzMGt6ajJPUmNVcUNkQW9sYmtDb05FZ3FycXhqQXNFVGF1VDJmWHlUa1NkeDZBSVNxaXQ3ZDRpMDVEZVJ5dzV2aFFuNW1HMHFLNjZxR3c4UTZDUQ?oc=5","date":"2026-01-26","type":"deal","source":"Insilico Medicine","summary":"Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies - Insilico Medicine","headline":"Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Car","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZ05qNnlsLUNvTWItZEtzSmdjTkM3alhjUG9CeHdFdGdfOWlrNXh5c2xXdHczQk4zalpEYUpWUG44MG9COWplT3FtaWcwS05BUVhtNlRieTJMSzNObklCMGxEQVRNb2xRTlgyRWdSbG9ObnB3ME1lMTJYWTFLTFI3NW5sMU1CVnUzSlIyU253VWJxcjQ1VGxoeDBfcmNwWkREV0VUT2VRVGZ5VGlZOEZ2UE5CUWg3OEVjamtqVmtxUGVfUQ?oc=5","date":"2025-12-16","type":"deal","source":"India Infoline","summary":"Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore - India Infoline","headline":"Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-15","type":"deal","source":"CNBC TV18","summary":"Senores Pharmaceuticals to acquire Apnar Pharma for enterprise value of ₹91 crore - CNBC TV18","headline":"Senores Pharmaceuticals to acquire Apnar Pharma for enterprise value of ₹91 crore - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOX1A1UnRIMW14c0JueWpvbmpFc2JFaXF4ckNfYnVfbDlhRkMzRTZOWHZlZ2docUZhWGh3azRQQ1dnWUlJS0NFVFRzWkJrb0hZZnk2LUdvaTBucmdCclRLNkM4Vlc0ZmFwbjlLc0hVWjA4YXFWTE1yYkd4XzVSOTJhR0pEZmYzbDVZME9IdEQ2MGZGN0pOUHE1V2JjZG5LYUU?oc=5","date":"2025-12-09","type":"trial","source":"PharmaTimes","summary":"Enterprise Therapeutics publishes results of phase 1 study of ETD001 - PharmaTimes","headline":"Enterprise Therapeutics publishes results of phase 1 study of ETD001","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxPQU1TUnFHWlNpdEZ3ck5SdmlzN3ROZWw2MGhIZ0lqMEpVMVNuN1dNUGVyaFRTajNEWURMSjVRbG5jWnBTTEJZLVhhYXFtMThNSEY5UUE0T080UWE2NFpUZ29aV0dZREcwWGxYMGtBYlRiRzRJanN2VzlETGt3NUJUbDVqLU1wOWF4ZDFLUktKdmVHLVhiTXZnUnNvNWJ4dXRfRFJnby02aTRTSkQzMWpEbWRBTGh1UkozT2lKZmc1X2NxR1N6Q1cycjN2Mm5yQ0tnSUZsMEFrYVNfRU9QZ0c0eUJEM05fZWRJbG1UNGd6Q3NEWmpNVGRtR2tGcy1lX3JVQWIya3hyam15UmppUjNtX0dOUXgtZEhpbEdXRUpVdWlKZ0hMQndGZDBqOF9XTG85VzhMM0p1ME9UOUF2STMwOG9nMA?oc=5","date":"2025-12-09","type":"trial","source":"businesswire.com","summary":"Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis - businesswire.com","headline":"Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cyst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPR2xRT29TeGRzYVd2dDdkemcwYzhKOWRtdER5Z1VlczAzemhNQXplVkJwMmdrcTVjQzNScWhiVFRSZTM2c3pBQ01Mc0QyZnRlNXRlMlcxLUZFbjZpZ2JUSTY3ZEZxam9QeVNVaUJfdmU3MGtSa0U4aWJCSVNBX2RhWlRlNC03bmFsa3ZZb0RFS2VsSUhjSUNoMkg4U0lFaEVfeVh6Mk9EQVpES0xmZloxZi0yYTFzRlliQ0E?oc=5","date":"2025-11-21","type":"pipeline","source":"YourStory.com","summary":"How Laborate Pharmaceuticals grew from a family enterprise to a global pharma company - YourStory.com","headline":"How Laborate Pharmaceuticals grew from a family enterprise to a global pharma company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9aVGNNNHk0aUF5dVFSWlQ2S2todnJsR2dYUjdWWGJha2Rlb202NDFDQko5ZTFla2Vydm1fbmY4ZW1TY1lldVZjVTJ3blZpeWNlak1tZERLd24tZDg3SnJRcFhITUJMWElxeWw0MTA3elJCSzI0ZGgw?oc=5","date":"2025-10-15","type":"deal","source":"Pharmaceutical Technology","summary":"BioCryst to buy Astria Therapeutics for $700m in enterprise value - Pharmaceutical Technology","headline":"BioCryst to buy Astria Therapeutics for $700m in enterprise value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQSWdabDluczV5cGRoNVRRc0ZIeGtRYTJ1WkNIellDTkR1eGpnYnhFT0dNRlY0NGpWX1oyVlIzUUgzWGRuX01lSW5SMEZKckZ2Um9IWXRDeG1xOHJRWG5BM0xuOE1TZ2VkVnhDaTBsanJOYVFxWGFHQlBya1loYloyRkxQYURfSFU4cjF0czFobnhmUGZJVVE?oc=5","date":"2025-05-08","type":"regulatory","source":"Yahoo Finance","summary":"EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Yahoo Finance","headline":"EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPRm1uYXhsM2xoemNiajA0dHhaT19qYmFWcHp0VlhDMEc0OG9Da1NEN01qUzZoRzZVX3hMNlc0dDd6dWNUNlRUd3owcFloWEtzRlhLUzNFbTBOeFY1UzBaWHZaMVVoMTAtX1N2MzhtSWdDdVBtVFdRNHZ1NlE3Y3haX1FMT2F0ZUpUM19iZGQwdTZSeDhKMVZLRlZ1NDBDakstUE91a1E4VThCTFprYU1FUUlhWUtuNUhUYjM2SmRIWWdScUV1MHR4OWN3bTlnMllfZ3BUSjd1aUpEd1VfX0wwaEFPWkFVZ3ZQc3NBaWd1M1F3UHpFNUpOZ2hUNmhxVkNHN3lZWnprZXUzel9mNTRvcQ?oc=5","date":"2024-09-26","type":"regulatory","source":"respiratory-therapy.com","summary":"FDA Awards Rare Pediatric Disease Designation to Investigational Cystic Fibrosis Treatment - respiratory-therapy.com","headline":"FDA Awards Rare Pediatric Disease Designation to Investigational Cystic Fibrosis Treatment - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOWXB2NWlNUHRUeGlHS1ZZYXlNVXN3UGRrMEx0WkVqc0REdlBVVHREbkJnOHlKUXVmVC0zY2Mwb2hMaGY4NENQQ2lBSk1UVVd0Qm5ZTXlNSjJGdk52MTlGV3FMUGxtSy1VeEtRWTN2bzREcnJBY0NkNDVYbHhTb2RZcUdjWlZoNXdpdmNfNnBVMFdUc0cwQmdqbXRpYkR2UHdtNUtOTDJDOGhHbHY2OFVVU2ZjbWlzUQ?oc=5","date":"2024-09-11","type":"regulatory","source":"cambridgenetwork.co.uk","summary":"Enterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory Affairs - cambridgenetwork.co.uk","headline":"Enterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory Affairs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wb05SY1JSQUNBTFZJQU1qaEJaYm4wS1pRd3lBamlJbUV2N0NDTTJabUxmVkx3VURVa0RRdV9naERTREVBRWttUzdSanJVMERzUW9QcGFzZjUzTV9LTThv?oc=5","date":"2024-08-14","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQNDZZVWNNSlh1QmVtVkZyMG5vNTRxbWhPdWduZ1pCbGlIZllUMkoxTC10R0RaNkNIZHRHMEVFa3psOGlhSjdfMDUxelAxUjRibDdJUEJGWHZuRXFtbVhBN3JRSUNOMWl1QktCekpNWG1DblhELWN5TU9rbDRKNXM2LXNDMHpMN19D?oc=5","date":"2020-10-07","type":"deal","source":"Pharmaceutical Technology","summary":"Roche Group acquires Enterprise Therapeutics’ potentiator portfolio - Pharmaceutical Technology","headline":"Roche Group acquires Enterprise Therapeutics’ potentiator portfolio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}